Table 6 Antibiotic treatment recommendations, according to [65]
From: Treatment of complicated intra-abdominal infections in the era of multi-drug resistant bacteria
| Â | Monotherapy | Combination therapy |
|---|---|---|
Diagnosis | Â | Â |
Secondary peritonitis | Â | Â |
low risk (localised peritonitis) | Ampicillin/Sulbactam | 2nd generation Cephalosporin + Metronidazol |
| Â | Carbapenem | 3rd generation Cephalosporin + Metronidazol |
low risk (diffuse peritonitis) | Ampicillin/Sulbactam | 2nd generation fluorochinolon + Metronidazol |
| Â | Piperacillin/Tazobactam | 3rd or 4th generation Cephalosporin + Metronidazol |
| Â | Carbapenem (group 1/2) | Â |
| Â | Fluorochinolon 4th generation | Â |
| Â | Tigecyclin | Â |
High risk | Piperacillin/Tazobactam | 4th generation Cephalosporin + Metronidazol |
| Â | Carbapenem (group 1/2) | Â |
| Â | Tigecyclin | Â |
Tertiary peritonitis | According to resistance from microbiology | Antifungal therapy in high risk patients |